Bergerac needed to make a decision quickly about in-house development or external acquisition due to inconsistency in the supply of cartridges.

True

False

0.16 points

QUESTION 2

Veterinary clinics found that having diagnostic equipment in-house led to a lower volume of testing.

True

False

0.16 points

QUESTION 3

Which of the following are true about Bergerac's competitors? (select all that apply)

		Bergerac's OmniVue product was at a higher price point than the comparable system offered by Abaxis
		Idexx had the largest product line and the best-established distribution network and sales force
		Bergerac saw an opportunity for itself to capture market share in small- and medium-sized veterinary practices
		Bergerac was the market share leader in the veterinary diagnostics instruments market

0.48 points

QUESTION 4

Which of the following statements are true of the build vs. buy decision? (select all that apply)

		McCarthy's analysis assumed a ~8% annual growth in production demand in the years ahead
		Bergerac's business already accounted for more than 90% of GenieTech's revenue
		In the "build" option, the machinery Bergerac would use would be less efficient than what GenieTech uses
		McCarthy calculated more annual savings with the in-house option at current rates of production

0.48 points

QUESTION 5

Analyses mentioned in the case suggested that the market for in-house diagnostics would grow in the next five years.

True

False

0.24 points

QUESTION 6

Which of the following statements are true of Bergerac's cartridge sourcing and production processes? (select all that apply)

		Despite dependencies on petrochemical prices, plastics suppliers enjoyed a market with very high margins
		Bergerac had to carry more inventory than they would like
		Bergerac sourced the plastic parts for its cartridges from only one supplier--GenieTech
		It was difficult for cartridge suppliers to respond to unexpected spikes in demand